The effect of melphalan dose and total body irradiation as reduced-intensity conditioning for acute lymphoblastic leukemia patients undergoing allogeneic stem cell transplantation.
Adolescent
Adult
Aged
Combined Modality Therapy
Female
Follow-Up Studies
Hematopoietic Stem Cell Transplantation
/ mortality
Humans
Male
Melphalan
/ therapeutic use
Middle Aged
Myeloablative Agonists
/ therapeutic use
Neoplasm Recurrence, Local
/ pathology
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ pathology
Prognosis
Retrospective Studies
Survival Rate
Transplantation Conditioning
/ mortality
Transplantation, Homologous
Whole-Body Irradiation
/ mortality
Young Adult
Transplant toxicity
clinical results
lymphoid leukemia
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
pubmed:
11
7
2019
medline:
20
9
2020
entrez:
11
7
2019
Statut:
ppublish
Résumé
To evaluate the prognostic impact of melphalan dose and total body irradiation (TBI) in acute lymphoblastic leukemia (ALL) patients undergoing reduced-intensity allogeneic transplantation, we retrospectively compared the outcomes between higher-dose melphalan (120-140 mg/m
Identifiants
pubmed: 31290354
doi: 10.1080/10428194.2019.1636986
doi:
Substances chimiques
Myeloablative Agonists
0
Melphalan
Q41OR9510P
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM